Barclays Maintains an 'Overweight' on Pfizer (PFE); King Acquisition: Good But Not Great
Tweet Send to a Friend
Barclays maintains an 'Overweight' rating on Pfizer Inc (NYSE: PFE), price target $21.
Barclays analyst says, "To use baseball parlance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "To use baseball parlance ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
